PVX is a novel peptide therapeutic developed by CYGNOS BioTech for the treatment of viral infections in non-food animals, including dogs, cats, horses, and birds. In vitro and pilot animal studies demonstrate significant antiviral activity across a broad spectrum of virus families. This proprietary technology is protected by eleven issued patents and has received an Investigational New Animal Drug (INAD) number from the FDA.